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Review Article
A review of randomised controlled trials
comparing ultrasound-guided foam
sclerotherapy with endothermal ablation
for the treatment of great saphenous
varicose veins
Huw OB Davies1, Matthew Popplewell1, Katy Darvall2,
Gareth Bate1 and Andrew W Bradbury1
Abstract
Objective: The last 10 years have seen the introduction into everyday clinical practice of a wide range of novel non-
surgical treatments for varicose veins. In July 2013, the UK National Institute for Health and Care Excellence recom-
mended the following treatment hierarchy for varicose veins: endothermal ablation, ultrasound-guided foam sclerother-
apy, surgery and compression hosiery. The aim of this paper is to review the randomised controlled trials that have
compared endothermal ablation and ultrasound-guided foam sclerotherapy to determine if the level 1 evidence base still
supports an ‘‘endothermal ablation first’’ strategy for the treatment of varicose veins.
Methods: A PubMed and OVID literature search (until 31 January 2015) was performed and randomised controlled
trials comparing endothermal ablation and ultrasound-guided foam sclerotherapy were obtained.
Results: Although anatomical success appeared higher with endothermal ablation than ultrasound-guided foam sclero-
therapy, clinical success and patient-reported outcomes measures were similar. Morbidity and complication rates were
very low and not significantly different between endothermal ablation and ultrasound-guided foam sclerotherapy.
Ultrasound-guided foam sclerotherapy was consistently less expensive that endothermal ablation.
Conclusions: All endovenous modalities appear to be successful and have a role in modern day practice. Although further
work is required to optimise ultrasound-guided foam sclerotherapy technique to maximise anatomical success and minimise
retreatment, the present level 1 evidence base shows there is no significant difference in clinical important outcomes
between ultrasound-guided foam sclerotherapy and endothermal ablation. As ultrasound-guided foam sclerotherapy is less
expensive, it is likely to be a more cost-effective option in most patients in most healthcare settings. Strict adherence to the
treatment hierarchy recommended by National Institute for Health and Care Excellence seems unjustified.
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Introduction
For almost 100 years, surgery was the only available
treatment for varicose veins (VV). However, over the
last 10 years a wide range of novel non-surgical, local
and tumescent anaesthetic, treatment modalities have
been described, evaluated and entered clinical practice
around the world.
In July 2013, the UK National Institute for Health
and Care Excellence (NICE) recommended (Clinical
Guideline, CG, 168) the following treatment hierarchy
for VV: endothermal ablation (ETA), ultrasound-
guided foam sclerotherapy (UGFS), surgery and
compression hosiery.1 This hierarchy was supported
in the Vascular Society of Great Britain and Ireland
(VSGBI) and Royal College of Surgeons (RCS)
Commissioning Guide published in December 20132
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and by the NICE Quality Standards (QS 67) which was
published in August 2014.3
Despite this, conventional surgery is still frequently
oﬀered to VV patients being treated within the UK
National Health Service4 and there is considerable con-
tinuing uncertainty regarding the clinical and cost-
eﬀectiveness of surgery, ETA and UGFS.5
The aim of this paper is to review the randomised
controlled trials (RCTs) that have compared ETA,
using either radiofrequency (RFA) or endovenous
laser ablation (EVLA), and UGFS to determine if the
level 1 evidence base still supports an ‘‘ETA ﬁrst’’ strat-
egy for the treatment of VV.
Methods
Search strategy
PubMed and OVID literature searches were performed
until 31 January 2015 using the terms RCT, sclerother-
apy, radiofrequency ablation, laser ablation, endovenous
and endothermal linked with varicose veins. Abstracts
were screened and the full papers obtained if they com-
pared UGFS with ETA for the treatment of VV.
Inclusion/exclusion criteria
Papers were included within the review if they were
classiﬁed as randomised controlled trials; all other
study types were excluded.
Analysis
ETA and UGFS RCT data were analysed in terms of
endovenous methodology, technical success, clinical
success, morbidity, complication rates, costs and time
to return to work.
Results
RCTs identified
Four RCTs, six publications, were identiﬁed
(Rasmussen et al.,6,7 Lattimer et al.,8,9 Biemans
et al.10 and Brittenden et al.11), all of which studied
only great saphenous (GSV) VV (only Rasmussen
allowed recurrent GSV VV, provided the GSV was
still present in the groin). Two papers described initial
results6,8 and were followed by further publications
reporting longer-term outcomes.7,9 Rasmussen com-
pared EVLA, RFA, UGFS and conventional surgery
(CS) in 580 legs, Lattimer compared EVLA and UGFS
in 100 legs, Biemans compared EVLA, UGFS and CS
in 240 legs, and Brittenden compared EVLA, UGFS
and CS in 798 legs (Table 1).
Comparison of endovenous techniques utilised
(Table 2)
Brittenden’s multi-centre trial did not specify laser
manufacturer, wavelength or ﬁbre type presumably as
these varied across hospitals. All of the other RCTs use
bare-tipped ﬁbres and lasers of varying wavelength:
Rasmussen 980 and 1470 nm (Ceralas D, Biolitec,
Jena Germany); Lattimer 1470 nm (ELVeS Painless
diode laser, Biolitec Inc, East Long Meadow, MA,
01028, USA); Biemans 940 nm (manufacturer not spe-
ciﬁed). For most treatments, the laser ﬁbre appears to
have been inserted into the GSV under ultrasound-
guidance at approximately the level of the knee, or at
Table 1. Comparison of RCT allocated treatments.
Trial
Legs randomised
EVLA RFA UGFS CS Total
Rasmussen 144 148 125
(124 received
treatment)
125
(124 received treatment)
580
Lattimer 50
(4 lost to follow-up)
– 50
(5 lost to
follow-up)
– 100
Biemans 80
(2 procedure failed)
– 80
(1 lost to follow up,
2 other intervention)
80
(3 procedure failed, 4 other
intervention, 8 no intervention)
240
Brittenden 292 – 212
(183 completed follow up)
294
(236 completed follow up)
(251 completed follow up)
798
RCT: randomised controlled trials; EVLA: endovenous laser ablation; RFA: radiofrequency ablation; UGFS: ultrasound-guided foam sclerotherapy;
CS: conventional surgery.
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the level of lowest incompetence in the thigh. The laser
ﬁbre tip was then advanced to within 2 cm of the
sapheno-femoral junction (SFJ) after which the GSV
was ablated by slow withdrawal of the catheter.
Rasmussen achieved a median of 69 J/cm, Lattimer
delivered a median of 69 J/cm, Biemans aimed for at
least 60 J/cm and Brittenden’s study aimed for at least
70 J/cm energy delivery. This was in concordance with
previous work suggesting that at least 60 J/cm energy
delivery is required for satisfactory vein closure.12 All
of the RCTs used tumescence anaesthesia and some
patients received light sedation. Rasmussen et al.6 and
Lattimer et al.8 performed EVLA with concurrent phle-
bectomies; Biemans et al.10 with either concurrent or
delayed (three months) phlebectomies; and Brittenden
et al.11 with UGFS to tributaries at six weeks (except
one site that performed concurrent phlebectomies).13
Only Rasmussen evaluated RFA and used a VNUS
ClosureFAST catheter (Covidien, Mansﬁeld, Mass,
USA) inserted under ultrasound-guidance into the
GSV just below the knee or at the lowest point of
reﬂux in the thigh. This was performed using tumescent
anaesthesia with light sedation and tributaries were
removed with concurrent phlebectomies.6
UGFS techniques varied considerably. Rasmussen
inserted a single cannula into the GSV just below the
knee and injected 3% polidocanol foam (volume not
speciﬁed) until the foam was visualised by ultrasound
at the SFJ and the GSV was contracted (in spasm)
throughout its length.6 Lattimer inserted a single can-
nula into the GSV at knee level and injected 1% sodium
tetradecyl sulphate (STS) using a median of 12ml/ses-
sion. If the GSV was 8mm in diameter, tumescence
anaesthesia was used to compress the vein before intro-
duction of STS foam. Lattimer performed further foam
treatments in 4.6% of patients who initially received
EVLA and in 56% of the patients who had been ran-
domised to foam. Biemans performed UGFS as per the
Second European Consensus14 using 3% polidocanol
(with a maximum of 10ml/session). Six patients
(4.6%) in the UGFS group had further foam treatment
in the ﬁrst six months. Brittenden did not provide infor-
mation on use of cannulas (numbers and sites) but sti-
pulated that 3% STS be used on truncal veins and 1%
STS on varicosities,13 with a maximum of 12ml/ses-
sion. At six weeks, 38% UGFS and 31% EVLA
patients underwent a further UGFS treatment. All
trials used foam volumes in accordance with manufac-
turers’ licences.
For RCTs including CS, SFJ ligation was performed
and the GSV stripped to the knee, or just below, with
concurrent phlebectomies. Rasmussen performed CS
using tumescence anaesthesia under light sedation;
Biemans used general anaesthetic; and Brittenden did
not specify the type of anaesthesia.
Technical success
Rasmussen deﬁned technical success as a closed or
absent GSV without reﬂux, and failure as an open seg-
ment of GSV> 10 cm in length or GSV unsuccessfully
stripped. Five GSVs were open after one month in the
UGFS group and these were re-treated. At one year, the
technical failures rates were 16.3% for UGFS, 5.8% for
EVLA and 4.8% for RFA (p< 0.001, 2)6; and at three
years they were 26.4% for UGFS, 6.8% for EVLA and
7% RFA (p< 0.0001, statistical test not stated).7
Lattimer deﬁned technical success as complete abla-
tion of GSV reﬂux (occlusion not required) and failure
as reﬂux anywhere in the above knee GSV. At three
months, the technical success rate (as deﬁned by
absence of above knee GSV reﬂux on duplex) was
80% in both the EVLA and UGFS groups; and at 15
months, global absence of reﬂux was 41% for EVLA
and 43% for UGFS. However, at 15 months, complete
GSV occlusion was observed in 95.5% of the EVLA,
and 67.4% of the UGFS, patients (p< 0.001, Fisher
exact test) at 15 months.
Biemans deﬁned technical success as complete oblit-
eration of, without ﬂow or reﬂux in, the mid-thigh
GSV. At 12 months, the technical success rate was
88.5% for EVLA and 72.7% for UGFS (p< 0.001, 2).
Brittenden deﬁned technical success according to
Kundu et al.15 as ‘successful ablation of the target
vein as demonstrated by a complete lack of ﬂow or
disappearance of vein by duplex ultrasound imaging
in the entire treated segment.’ At six weeks, the tech-
nical success rate was 83% for EVLA and 54.6% for
UGFS (p 0.01, statistical test not stated).
Clinical success
Rasmussen reported clinical success using the Venous
Clinical Severity Score (VCSS),16 Aberdeen Varicose
Vein Questionnaire (AVVQ),17 Short Form-36
(SF-36) (QualityMetric, Lincoln, Rhode Island,
USA) and visual analogue scores (VAS) for pain. All
three improved signiﬁcantly in all four patients groups
and there was no diﬀerence between EVLA, RFA,
UGFS and CS at one or three years.
Lattimer reported clinical success using the VCSS,
AVVQ and the Saphenous Treatment Score18. All
three improved signiﬁcantly in both groups and there
was no diﬀerence between EVLA and UGFS out to 15
months; although seven-day pain scores were signiﬁ-
cantly higher with EVLA.
Biemans reported clinical success using the chronic
venous insuﬃciency quality of life (QoL) questionnaire
(CIVIQ)19 and EuroQoL 5D (EQ-5D) (EuroQol,
Rotterdam, Netherlands). These both improved at
three months and there was no diﬀerence between
EVLA and UGFS out to one year.
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Brittenden reported clinical success using AVVQ,
VCSS, EQ-5D, SF-36 and clinical vein appearance.
At six months both EVLA and UGFS showed
improvement in AVVQ and VCSS, with no statistical
diﬀerence between EVLA and UGFS reported. Both
EQ-5D and the physical component of SF-36 showed
improvement in all groups, with no statistical diﬀerence
between groups. The SF-36 mental component was
slightly better in EVLA vs. UGFS (p 0.048, using gen-
eral linear model with adjustments for covariates used
in minimisation algorithm) and all groups improved.
Patient and nurses reported no diﬀerence between
UGFS and EVLA in terms of residual veins at six
weeks, but fewer residual veins were reported by
patients (not by nurses) in EVLA compared to UGFS
at six months.
Morbidity and complication rates
Morbidity and complication rates were very low in all
RCTs in all treatment groups. Rasmussen reported one
iliac vein thrombosis with pulmonary embolus one
week after UGFS. Lattimer reported no serious com-
plications except one EVLA patient who developed a
common femoral vein thrombosis. Biemans noted a low
frequency of minor morbidity (such as hyperpigmenta-
tion, thrombophlebitis and paraesthesia), which was
not statistically signiﬁcant between groups. Brittenden
reported no diﬀerence between groups in terms of ser-
ious adverse events (these included deep vein throm-
bosis and pain).
Costs and return to work
Only Rasmussen, Lattimer and Brittenden (reported by
Tassie et al.20) looked at these outcomes. Rasmussen
reported a quicker return to work after UGFS and
RFA when compared to EVLA. Treatment costs were
E994 for UGFS, E1360 EVLA and E1436 RFA (cost
of catheter higher than for EVLA). If time lost from
work is included overall costs were E1554 UGFS,
E2200 EVLA and E1996 RFA. Lattimer also found a
cost advantage with UGFS (£230.24) compared to
EVLA (£724.72), even if further foam treatments were
required. Brittenden’s trial demonstrated treatment
costs of £245 for UGFS and £737 for EVLA (the dif-
ference appears to partly be due to increased consum-
able costs). At six months total health service costs
(including follow up and unplanned use of health ser-
vice), UGFS costs were £465 and EVLA were £975.
Discussion
Although there are a large number of observational
studies available in the literature, randomised data
comparing ETA with UGFS remains limited.
Furthermore, there are important diﬀerences between
the RCTs in terms of the:
1. Technology and techniques used for ablating the
GSV as well the tributaries and varices themselves.
2. Deﬁnitions of technical and clinical success and
failure.
3. Limited duration and completeness of follow.
4. Variable estimates of cost.
It is therefore diﬃcult to draw any ﬁrm conclusions
regarding the relative clinical and cost-eﬀectiveness of
ETA and UGFS for the treatment of primary GSV VV.
Furthermore, the available RCTs evaluated only
primary GSV disease and did not study the many
other patterns of VV disease seen in everyday clinical
practice; and only Rasmussen allowed the inclusion of
GSV recurrence within speciﬁed parameters. Only
Brittenden’s supplementary table speciﬁed numbers of
patients excluded due to technically unsuitable veins for
ETA (8.5% of approached patients, although some
patients may have also been excluded for technical
unsuitability under the title ‘vein-related – no further
information,’ 179 patients).
However, we suggest that the available randomised
data do allow a number of observations to be made:
1. All of the endovenous modalities evaluated are
extremely safe being associated with a low compli-
cation rate and little signiﬁcant morbidity.21,22
2. All of the RCTs demonstrated that all of the treat-
ments evaluated led to a statistically signiﬁcant
and clinically important improvement in the symp-
toms and signs of VV disease.
3. Technical failure is fairly consistently reported to
be higher after UGFS than with ETA although
closure rates after ETA in RCTs do not match
the very high rates reported in other studies.23–26
4. Diﬀerences in technical success did not relate to
diﬀerences in clinical (patient reported) outcomes
in any of the RCTs and the value of ‘technical
success’ as a useful end-point is questionable.
5. RFA is a highly standardised technique with cur-
rently a single device dominating the market.
6. However, this is not the case with EVLA where a
large number of diﬀerent laser technologies, that
may have important diﬀerences, are currently
available.
7. For the purposes of their recommendations, in
2012–2013 NICE decided to consider all ETA
techniques together. While, at the time, that was
justiﬁed on the basis of the available data, tech-
nology continues to develop rapidly in this ﬁeld.
As such, it is likely that going forward there will be
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outcome heterogeneity with diﬀerent manufac-
turers’ products.21,27
8. UGFS is an even more heterogeneous treatment
modality than ETA with many variables such as
the numbers and siting of cannulas, chemical
nature, strength and volume of sclerosant used,
method of foam preparation, post-procedure com-
pression regime and strategy for re-treatment and
aspiration likely to have a major impact on
outcomes.
9. The available RCTs have been criticised for using
UGFS techniques that would not now be accepted
as ‘standard of care’ but, as noted above, that is a
criticism that might also be levelled in terms of the
ETA technologies evaluated.28–33
10. Although there is a growing consensus that
patient-reported (subjective) outcomes measures
(PROMs) are more important that technical
(duplex) or physician-reported (objective) out-
comes, currently available PROMs tools are
imperfect and may miss important (to the patient)
diﬀerences between diﬀerent treatments,16–19 such
as recovery time and time oﬀ work.
11. Although due to diﬀerences in methods for esti-
mating treatment costs it is diﬃcult to draw any
conclusions, it seems likely that local anaesthetic
treatment will be more cost-eﬀective than treat-
ment performed under general anaesthesia.
12. Only Brittenden’s group calculated QALYs – ﬁnd-
ing that EVLA had a slightly higher QALYs score
than UGFS at ﬁve years;20 however, this score was
extrapolated from six month follow-up data.
13. All of the RCTs reported UGFS to be less expen-
sive that ETA and give the lack of any diﬀerence
in clinical outcomes (QoL) it is reasonable to sug-
gest that UGFS will be the more cost-eﬀective
option in most patients in most healthcare set-
tings, although this will require more data from
long-term follow-up of patients included within
these studies to accurately conﬁrm.
Conclusion
All endovenous methods appear to have a role in the
treatment of VV. In terms of patient-reported quality of
life (QoL), improvement is seen in all groups with no
statistical diﬀerence. Anatomical success measured with
duplex ultrasonography is improved with ETA treat-
ments compared to UGFS, but this may be because
of lower technical expertise in a treatment that is
more reliant on experience than ETA methods.
UGFS requires meticulous technique to provide opti-
mal outcomes with arguably more consideration to
treatment tactics than required for ETA methods.
UGFS is also more ﬂexible in its ability to treat recur-
rence or particularly tortuous VVs. There appears to be
a signiﬁcant cost advantage to UGFS over EVLA and
RFA, even if further treatment sessions are required.
Although further work is required to optimise UGFS
technique to maximise anatomical success and minim-
ise retreatment, the present level 1 evidence base shows
it is likely that there is no signiﬁcant diﬀerence in
clinical important outcomes between UGFS and
ETA. As such strict adherence to the treatment hier-
archy recommended by NICE seems unjustiﬁed.
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